Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00147719 · ClinicalTrials.gov registry record · Phase 3
WelChol® With Metformin in Treating Patients With Type 2 Diabetes
A Phase 3 study of Type 2 Diabetes, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT00147719 is a Phase 3 study of Type 2 Diabetes that has completed, run by Daiichi Sankyo. The registered enrollment target is 300 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT00147719, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to metformin alone or in combination with other anti-diabetic drugs.
Conditions Studied
Interventions
- DRUG Colesevelam hydrochloride
Study Locations (20)
California
- - Beverly Hills
- - Carmichael
- - Fresno
- - Irvine
- - La Jolla
- - Los Gatos
- - San Diego
- - Spring Valley
- - West Hills
Florida
- - Coco Beach
- - Largo
- - Miami
- - Pembroke Pines
- - West Palm Beach
Arkansas
- CRO - Jonesboro
District of Columbia
- - Washington D.C.
Georgia
- - Atlanta
Indiana
- - Evansville
Kentucky
- - Louisville
Michigan
- - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-06 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00147719
The ClinicalTrials.gov registry entry for NCT00147719 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (73% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Colesevelam hydrochloride is the first listed.
NCT00147719 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00147719 about?
NCT00147719 is a clinical study titled "WelChol® With Metformin in Treating Patients With Type 2 Diabetes". The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to metformin alone or in combination with other anti-diabetic drugs.
What is the current status of trial NCT00147719?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2004-06. Estimated completion is 2006-07.
What conditions does trial NCT00147719 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT00147719?
The interventions under investigation include: Colesevelam hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00147719?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00147719 being conducted?
This trial has 20 study locations across Arkansas, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.